Lance Alstodt - Nov 4, 2021 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role
President, CEO, COB, Director
Signature
/s/ Lance Alstodt
Stock symbol
BRTX
Transactions as of
Nov 4, 2021
Transactions value $
$0
Form type
4
Date filed
11/8/2021, 04:30 PM
Next filing
Nov 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BRTX Common Stock 151K Nov 4, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BRTX Stock Option Disposed to Issuer $0 -293K -100% $0.00* 0 Nov 4, 2021 Common Stock 293K $47.60 Direct F2, F3, F5
transaction BRTX Stock Option Award $0 +293K $0.00 293K Nov 4, 2021 Common Stock 293K $13.50 Direct F4, F5
transaction BRTX Stock Option Award $0 +42.1K $0.00 42.1K Nov 4, 2021 Common Stock 42.1K $13.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 146,740 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 48,914 shares on March 18, 2022 and 48,913 shares on each of March 18, 2023 and March 18, 2024.
F2 Reflects a 1-for-4,000 reverse split effected by the issuer on October 27, 2021.
F3 The option vests to the extent of 146,740 shares on March 18, 2021, 73,370 shares on March 18, 2022 and 73,369 shares on March 18, 2023.
F4 The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F5 The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with an adjusted exercise price and vesting dates.
F6 The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.